Rani Therapeutics Holdings, Inc. has launched a Phase 1 clinical trial of RT‑114, an orally delivered GLP‑1/GLP‑2 dual agonist (PG‑102) developed in partnership with ProGen. The study will compare the safety, tolerability, bioavailability, pharmacokinetics, and weight‑loss effects of the RaniPill® capsule against the standard subcutaneous injection.
The trial marks the first human evaluation of RT‑114 and represents a critical validation of Rani’s proprietary RaniPill platform, which aims to deliver biologics orally. A successful oral therapy could tap into a $100 billion obesity market and position Rani as a pioneer in a space dominated by injectable treatments.
Rani’s recent liquidity improvements—highlighted by a $60.3 million private placement—have bolstered its cash position, but the company remains in a high‑cash‑burn phase typical of clinical‑stage biotechs. CEO Talat Imran noted that the Phase 1 milestone “provides powerful validation of the modality and the unmet need it addresses,” while acknowledging that continued investment will be required to advance the program through later‑stage trials.
The company’s financial profile shows that, despite the cash burn, the milestone could unlock future funding and regulatory progress. Management has emphasized that the RaniPill platform’s potential to improve patient compliance and reduce administration costs could create a competitive advantage in the obesity treatment landscape.
Talat Imran added, “As we initiate this trial and advance RT‑114 through clinical development, we view this progress as powerful validation of the modality and the unmet need it addresses. We believe that a tolerable and efficacious oral option has the potential to expand access, improve patient experience, and meaningfully reshape the obesity treatment paradigm.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.